Rycarfa 50 mg/ml Solution for Injection for Dogs and Cats

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)

Aktīvā sastāvdaļa:

Carprofen

Pieejams no:

Krka d.d., Novo Mesto

ATĶ kods:

QM01AE91

SNN (starptautisko nepatentēto nosaukumu):

Carprofen

Zāļu forma:

Solution for injection

Receptes veids:

POM-V - Prescription Only Medicine – Veterinarian

Ārstniecības grupa:

Cats, Dogs

Ārstniecības joma:

Anti Inflammatory NSAID

Autorizācija statuss:

Authorized

Autorizācija datums:

2014-03-13

Produkta apraksts

Revised: February 2019
AN: 00133/2018
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rycarfa 50 mg/ml solution for injection for dogs and cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Carprofen
50 mg
EXCIPIENT:
Benzyl alcohol (E1519)
10 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, pale yellow coloured solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dogs: For the control of post-operative pain and inflammation
following orthopaedic
and soft tissue (including intraocular) surgery.
Cats: For the control of post-operative pain following surgery.
4.3
CONTRAINDICATIONS
Do not use in animals suffering from cardiac, hepatic or renal disease
or
gastrointestinal problems, where there is a possibility of
gastrointestinal ulceration or
bleeding, or hypersensitivity to carprofen or any other NSAIDs or any
excipients of
this product.
Do not administer by intramuscular injection.
Do not use after surgery which was associated with considerable blood
loss.
Do not use in cats on repeated occasions.
Do not use in cats less than 5 months of age.
Revised: February 2019
AN: 00133/2018
Page 2 of 6
Do not use in dogs less than 10 weeks of age.
See also section 4.7.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Do not exceed the recommended dose or duration of treatment.
Due to the longer half life in cats and narrower therapeutic index,
particular care
should be taken not to exceed the recommended dose and the dose should
not be
repeated.
Use in aged dogs and cats may involve additional risk.
If such use cannot be avoided, such animals may require a reduced
dosage and
careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as
there is a
potential risk of increased renal toxicity.
NSAIDs can cause inhibition